Predictive Biomarkers in the Treatment of Her2-Positive Breast Cancer: An Ongoing Challenge
- 23 March 2016
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 12 (11) , 1413-1428
Abstract
The transmembrane tyrosine kinase receptor HER2 is overexpressed in 20% of invasive breast cancers and is associated with more aggressive disease. Until the advent of targeted agents, HER2 was associated with worse outcome. Trastuzumab, a recombinant humanized anti-HER2 monoclonal antibody, combined with chemotherapy improves disease-free and overall survival in both primary and metastatic tumors and represents a foundation of care for patients with HER2-positive breast cancers. However, a sizeable number of patients do not respond to this reagent, indicating the need for a biomarker able to recognize resistant tumors. Here, we review various studies on mechanisms of action and resistance to trastuzumab that have proven relevant in understanding how tumor care can be tailored to all HER2-positive patients.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (2014/5359)
This publication has 95 references indexed in Scilit:
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and TreatmentFrontiers in Oncology, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Activity and resistance of trastuzumab according to different clinical settingsCancer Treatment Reviews, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN InactivationCancer Cell, 2010
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translationThe EMBO Journal, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004